Education
About Us
Working with TipRanks
Follow Us
Wakamoto Pharmaceutical Co., Ltd. (JP:4512)
:4512
Total Valuation
Wakamoto Pharmaceutical Co., Ltd. has a market cap or net worth of ¥10.62B. The enterprise value is ¥8.42B.
Market Cap¥10.62B
Enterprise Value¥8.42B
Share Statistics
Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,838,326
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Wakamoto Pharmaceutical Co., Ltd.’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -30.28%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)-30.28%
Return on Capital Employed (ROCE)-0.04
Revenue Per Employee19.33M
Profits Per Employee159.90K
Employee Count403
Asset Turnover0.52
Inventory Turnover1.37
Valuation Ratios
The current PE Ratio of Wakamoto Pharmaceutical Co., Ltd. is 160.0. Wakamoto Pharmaceutical Co., Ltd.’s PEG ratio is ―.
PE Ratio160.0
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.95
Price to FCF0.00
Price to Operating Cash Flow48.28
PEG Ratio―
Income Statement
In the last 12 months, Wakamoto Pharmaceutical Co., Ltd. had revenue of 7.79B and earned 64.44M in profits. Earnings per share was 1.86.
Revenue7.79B
Gross Profit3.62B
Operating Income-457.80M
Pretax Income7.46M
Net Income64.44M
EBITDA438.68M
Earnings Per Share (EPS)1.86
Cash Flow
In the last 12 months, operating cash flow was 820.56M and capital expenditures 0.00, giving a free cash flow of 820.56M billion.
Operating Cash Flow820.56M
Free Cash Flow820.56M
Free Cash Flow per Share23.55
Dividends & Yields
Wakamoto Pharmaceutical Co., Ltd. pays an annual dividend of ¥3, resulting in a dividend yield of 0.98%
Dividend Per Share¥3
Dividend Yield0.98%
Payout Ratio-314.14%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.27
52-Week Price Change27.61%
50-Day Moving Average299.56
200-Day Moving Average274.21
Relative Strength Index (RSI)59.61
Average Volume (3m)465.31K
Important Dates
Wakamoto Pharmaceutical Co., Ltd. upcoming earnings date is Nov 5, 2025, TBA (Confirmed).
Last Earnings DateAug 1, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Wakamoto Pharmaceutical Co., Ltd. as a current ratio of 4.38, with Debt / Equity ratio of 0.86%
Current Ratio4.38
Quick Ratio2.88
Debt to Market Cap<0.01
Net Debt to EBITDA-6.51
Interest Coverage Ratio-519.04
Taxes
In the past 12 months, Wakamoto Pharmaceutical Co., Ltd. has paid -56.98M in taxes.
Income Tax-56.98M
Effective Tax Rate-7.64
Enterprise Valuation
Wakamoto Pharmaceutical Co., Ltd. EV to EBITDA ratio is 18.57, with an EV/FCF ratio of -7.81.
EV to Sales1.05
EV to EBITDA18.57
EV to Free Cash Flow-7.81
EV to Operating Cash Flow-13.75
Balance Sheet
Wakamoto Pharmaceutical Co., Ltd. has ¥3.56B in cash and marketable securities with ¥100.00M in debt, giving a net cash position of -¥3.46B billion.
Cash & Marketable Securities¥3.56B
Total Debt¥100.00M
Net Cash-¥3.46B
Net Cash Per Share-¥99.33
Tangible Book Value Per Share¥334.53
Margins
Gross margin is 46.50%, with operating margin of -5.88%, and net profit margin of 0.83%.
Gross Margin46.50%
Operating Margin-5.88%
Pretax Margin0.10%
Net Profit Margin0.83%
EBITDA Margin5.63%
EBIT Margin0.11%
Analyst Forecast
The average price target for Wakamoto Pharmaceutical Co., Ltd. is ¥292.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target¥292.00
Price Target Upside-4.58% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast4.00%
EPS Growth Forecast-933.04%